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Background. We evaluated reliability and clinical usefulness of genotypic resistance testing (GRT) in patients for
whom combination antiretroviral therapy (cART) was unsuccessful with viremia levels 50–1000 copies/mL, for
whom GRT is generally not recommended by current guidelines.
Methods. The genotyping success rate was evaluated in 12 828 human immunodeﬁciency virus type 1 (HIV-1) plas-
ma samples with viremia >50 copies/mL, tested using the commercial ViroSeq HIV-1 Genotyping System or a home-
made system. Phylogenetic analysis was performed to test the reliability and reproducibility of the GRT at low-level
viremia (LLV). Drug resistance was evaluated in 3895 samples from 2200 patients for whom treatment was unsuccessful
(viremia >50 copies/mL) by considering the resistance mutations paneled in the 2013 International Antiviral Society list.
Results. Overall, the success rate of ampliﬁcation/sequencing was 96.4%. Viremia levels of 50–200 and 201–500 cop-
ies/mL afforded success rates of 67.2% and 88.1%, respectively, reaching 93.2% at 501–1000 copies/mL and ≥97.3%
above 1000 copies/mL. A high homology among sequences belonging to the same subject for 96.4% of patients analyzed
was found. The overall resistance prevalence was 74%. Drug resistance was commonly found also at LLV. In particular, by
stratifying for different viremia ranges, detection of resistancewas as follows: 50–200 copies/mL = 52.8%; 201–500 = 70%;
501–1000 = 74%; 1001–10 000 = 86.1%; 10 001–100 000 = 76.7%; and >100 000 = 63% (P < .001). Similar bell-shaped re-
sults were found when the GRT analysis was restricted to 2008–2012, although at a slightly lower prevalence.
Conclusions. In patients failing cART with LLV, HIV-1 genotyping provides reliable and reproducible results that
are informative about emerging drug resistance.
Keywords. HIV-1 genotyping; HIV-1 low viremia; drug resistance; phylogenesis; clinical outcome.
Over the past 15 years, antiretroviral therapy for the
treatment of human immunodeﬁciency virus type 1
(HIV-1) infection has improved; to date, about 90% of
HIV-1–infected patients who start a ﬁrst-line regimen
achieve virologic suppression [1–10]. However, therapy
failures are still observed in clinical practice; particu-
larly at early time points, many are characterized by
low-level viremia (LLV). Standard-of-care management
recommends use of resistance testing to guide further
therapy. One area of uncertainty is the evaluation of
treatment failure in patients with LLV. Treatment
guidelines usually do not recommend genotypic resis-
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tance testing (GRT) for plasma HIV RNA <500–1000 copies/
mL. This potential limitation of GRT mostly derives from the
detection limits of commercial assays, as well as by the technical
difﬁculty of many laboratories in obtaining consistent results
with such LLV, yet some studies support the use of GRT, and
laboratories increasingly report success in performing geno-
types at this level [11–26].
In this study, we provide data to support reliability and use-
fulness of GRT at viremia levels ≤500–1000 copies/mL by ana-
lyzing a large population of HIV-1–infected patients followed in
central Italy who underwent GRT in routine clinical practice.
Moreover, we evaluated whether different viremia levels affect
the detection of drug resistance in HIV-1–infected patients
who failed therapy.
MATERIALS AND METHODS
Patients
This retrospective study included 13 926 HIV-1 plasma samples
that were genotyped during 1999–2012 in 2 clinical centers in
Rome (Italy) for routine clinical purposes. Sample information
(date of sampling, ﬁnal results of sequencing, nucleotide se-
quences obtained, mutations found in each sequence), together
with the data of patients for whom genotyping was performed
(ie, viroimmunologic, clinical, and therapeutic data) were re-
corded in an anonymous database.
For each sample, viremia value at genotyping was known. We
focused our analyses on samples with viremia >50 copies/mL
(N = 12 828) that were stratiﬁed in 6 groups according to differ-
ent viremia ranks (copies/mL): 50–200, 201–500, 501–1000,
1001–10 000, 10 001–100 000, and >100 000.
HIV-1 RNA Load
Depending on methodologies available during 1999–2012, plas-
ma viremia was determined using 3 different assays: the bDNA
version 3.0 (until January 2009; Bayer Corporation, Diagnostics
Division, Tarrytown, New York), the Abbott RealTime HIV-1
(February 2009–February 2012; Abbott, Chicago, Illinois) and
the Roche Cobas CA/CTM version 2.0 (starting from March
2012; Roche, Mannheim, Germany). These assays quantify
HIV-1 RNA in the range of 50–500 000 copies/mL, 40–
10 000 000 copies/mL, and 20–10 000 000 copies/mL, respec-
tively. Previous studies demonstrated the results obtained by
these assays to be well correlated, with a difference of >0.5
log10 copies/mL, only for a few samples [27–29].
HIV-1 pol Sequencing
HIV-1 genotype analysis was performed on plasma samples by
using either the ViroSeq HIV-1 genotyping system (Abbott Mo-
lecular) and/or a homemade system, designed to improve the per-
formance of the ViroSeq system itself [30]. Indeed, genotyping
success by this commercial kit is generally guaranteed for samples
with viremia ≥2000 copies/mL [31, 32]. Therefore, some steps of
the ViroSeq system were modiﬁed, to also test HIV-1 pol sequenc-
es in subjects with viremia <2000 copies/mL. All of the details on
the ampliﬁcation and sequencing procedures can be found in the
Supplementary Methods and Supplementary Figure 1.
Subtyping Analysis
All HIV-1 pol sequences were aligned in Bio-Edit and compared
to reference sequences for major HIV-1 subtypes and circular
recombinant forms (CRFs), available at the Los Alamos data-
base (http://www.hiv.lanl.gov); a phylogenetic tree was per-
formed. To analyze trends in subtype genetic diversity over
time, genetic distances were calculated by using the maxi-
mum-likelihood method in MEGA (http://www.megasoftware.
net/), by using Kimura 2-parameter model as the best-ﬁtting
evolution model for tree reconstruction [33]. The tree was
shown by using the graphical user interface FigTree. Subtype
classiﬁcation was conﬁrmed also by the REGA subtype tool
(http://www.bioafrica.net/rega-genotype/html/subtypinghiv.
html), the COMET subtype tool (http://comet.retrovirology.lu/),
and the DataMonkey subtype tool (http://www.datamonkey.
org/dataupload_scueal.php). To improve the accuracy of re-
combinant and unique forms, RDP3 software (http://web.cbio.
uct.ac.za/~darren/rdp.html) and Splits Tree software (http://en.
bio-soft.net/tree/SplitsTree.html) were used.
Evaluation of Genotypic Success Rate and Genotyping Reliability
Genotyping success rate was determined on the overall population
and according to the different viremia ranks (50–200, 201–500,
501–1000, 1001–10 000, 10 001–100 000, and >100 000 copies/
mL), regardless of the genotyping platform upgrades (equipment,
kits, and reagents) that occurred from 1999 to 2012.
To ensure that there was no cross-contamination of samples
analyzed and to test genotyping reliability for samples with
viremia ≤500 copies/mL, a phylogenetic analysis was per-
formed on a subgroup of 1613 pol sequences, obtained from 470
patients with at least 1 GRT performed on samples with viremia
≤500 copies/mL and at least 1 GRT with viremia >1000 copies/
mL. The phylogenetic analysis of pol sequences was performed
by using the Kimura 2-parameter model of MEGAversion 5.05,
with the same parameters as previously described [33].
Evaluation of Resistance in Patients Who Had Failed Therapy
The prevalence of drug resistance was evaluated, and stratiﬁed
according to different viremia levels, in a subset of 3895 samples
successfully genotyped from 2200 patients with complete ther-
apeutic history, for whom a GRT was required because of viro-
logic failure (deﬁned as viremia >50 copies/mL). Resistance to
an antiretroviral drug class was deﬁned by the presence of at
least 1 primary resistance mutation (PRM) included in the mu-
tation list paneled by the International Antiviral Society in 2013
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[34], considering the nucleos(t)ide reverse transcriptase inhibi-
tors (NRTIs), nonnucleos(t)ide reverse transcriptase inhibitors
(NNRTIs), and protease inhibitors (PIs). In particular, we have
deﬁned (i) the resistance to any drug class in the overall samples
analyzed; (ii) the resistance to NRTIs among samples from pa-
tients who received regimens that contained NRTIs; (iii) the re-
sistance to NNRTIs among samples from patients who received
regimens that contained NNRTIs; (iv) the resistance to PIs
among samples from patients who received regimens that con-
tained ritonavir-boosted PIs (PI/r); and (v) the resistance to PIs
among samples from patients who received regimens that con-
tained ritonavir-unboosted PIs.
To better understand the clinical relevance of GRT in patients
failing with LLV at the time of modern anti-HIV therapies, the
prevalence of single PRMs was also evaluated on the 1317 samples
from patients for whom a GRT was required because of virologic
failure in the years 2008–2012. This analysis was performed by
dividing the samples into 2 groups according to viremia levels
≤1000 copies/mL (n = 436) or >1000 copies/mL (n = 881).
Patient Outcome Analysis
To evaluate the effect of LLV resistance on subsequent virologic
outcome, further analyses were restricted to 51 previously drug-
naive patients on ﬁrst-line regimens for whom a GRT was re-
quested at viremia levels of 50–1000 copies/mL. Patients were
included only if they were followed as long as they were receiv-
ing constant therapy without any changes or interruptions.
Statistical Analysis
Potential differences among the different viremia groups were
evaluated as follows: (i) for the categorical variables, by the χ2
test for trend (to compare all viremia groups) and Pearson χ2
test or Fisher exact test when expected frequencies were <5
(to compare 2 viremia groups at a time); and (ii) for the contin-
uous variables, by the Kruskal-Wallis test (to compare all vire-
mia groups). Regarding the virologic outcome, Kaplan-Meier
analysis was used to evaluate the probability of reaching viremia
>1000 copies/mL after LLV.
In all the analyses performed, P < .05 was considered as stat-
istically signiﬁcant. The statistical programs used were R open
source software (version 2.15.1) and SPSS version 19 for Win-
dows (SPSS Inc, Chicago, Illinois).
RESULTS
Study Population
Table 1 shows the characteristics of 12 828 of 13 926 plasma
samples with viremia >50 copies/mL, processed for genotyping
in routine clinical practice from 1999 to 2012. Among them,
4861 (37.9%) were obtained from 4111 drug-naive patients,
and 7967 (62.1%) from 3841 drug-experienced patients.
Among drug-experienced patients, viremia levels of 50–1000
copies/mL accounted for 19.2% (1535/7967) of total genotypic
requests (Figure 1). This prevalence signiﬁcantly increased over
time, from 1.5% in 1999–2001 to 28.4% in 2012 (P < .001). A
consistent proportion of samples with LLV was with viremia
50–500 copies/mL (1158/1535 [75.4%] vs 377 [24.6%] with vi-
remia 501–1000 copies/mL).
Phylogenetic analysis revealed that the B subtype was the
most prevalent strain (80.1%). All the other subtypes were pre-
sent with a prevalence <5%; the most prevalent ones were the
recombinant form CRF02_AG (4.7%) and the subtypes C
(4.3%) and F (3.3%).
Genotyping Success Rate
The overall success rate of genotype ampliﬁcation and sequenc-
ing was 96.4%. The rate of success was 93.2% for samples with
viremia levels 501–1000 copies/mL, 88.1% for those with vire-
mia 201–500 copies/mL, and decreased to a still-relevant
67.2% for viremia 50–200 copies/mL (Table 2). The genotyping
success rate was independent of subtype in all viremia groups
(Table 2). By focusing the attention on the 3 most prevalent
Table 1. Characteristics of Plasma Samples With HIV-1 RNA
>50 Copies/mL at Genotypic Resistance Testing
Variable No. (%)
Patients (N = 7518)
Patients with only 1 sample 4950 (65.8)
Patients with >1 sample 2568 (34.2)
Samples (N = 12 828)
From drug-naive patients 4861 (37.9)
From drug-experienced patients 7967 (62.1)
Samples with subtype information availablea
B 10 212 (80.1)
CRF02_AG 598 (4.7)
C 545 (4.3)
F 422 (3.3)
BFb 312 (2.4)
G 173 (1.4)
A 157 (1.2)
Other 326 (2.6)
Samples according to viremia ranges, copies/mL
50–200 769 (6.0)
201–500 489 (3.8)
501–1000 444 (3.4)
1001–10 000 2435 (19.0)
10 001–100 000 4845 (37.8)
>100 000 3846 (30.0)
Abbreviation: HIV-1, human immunodeficiency virus type 1.
a Subtype information was available for 12 745 of 12 828 (99.4%) samples.
b Including CRF12, CRF17, CRF28, CRF29, CRF40.
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non-B subtypes analyzed (C, F, CRF02_AG), no differences in
the success rate were found (data not shown).
Interestingly, the additional use of a nested polymerase chain
reaction (PCR) (or modiﬁed ampliﬁcation protocol; see Sup-
plementary Methods and Supplementary Figure 1) has
signiﬁcantly improved the overall success rate in samples with
LLV (P < .001). In particular, the nested ampliﬁcation contrib-
uted to 60.4%, 55.3%, and 44.0% of the total genotypic successes
with viremia levels 50–200, 201–500, and 501–1000 copies/mL,
respectively. In samples with viremia levels >1000 copies/mL,
the contribution of nested ampliﬁcation was less relevant
(from 19.2% to 3.6%; data not shown).
Genotyping Reliability
To test genotyping reliability for samples with VL ≤1000 cop-
ies/mL, we performed phylogenetic analysis on 1613 sequences
from 470 patients having at least 1 genotypic sample with vire-
mia 50–1000 copies/mL and at least another with viremia
>1000 copies/mL. By evaluating each cluster, we found that se-
quences belonging to the same subject showed a high homology
(bootstrap value >90%) in 96.4% of cases (453/470 patients)
(Supplementary Figure 2). Only 25 of 1613 sequences (1.5%)
of the remaining 17 patients did not properly cluster within
the same subject.
Evaluation of Resistance According to Different Viremia Ranges
in Patients Failing Therapy
Prevalence of PRMs was analyzed on 3895 samples from a sub-
group of 2200 patients at therapy failure. Patient characteristics
of this subgroup are reported in Supplementary Table 1. Over-
all, the median year of genotyping was 2006 (interquartile
range, 2003–2009), and the proportion of samples from subtype
B infected–patients was about 86%.
Figure 1. Genotypic requests for 7967 plasma samples from drug experienced patients, 1999–2012. The proportions of genotypic requests stratiﬁed by
different viremia ranges are represented in different shades from black to white. The differences of genotypic requests over the years in patients with
viremia levels 50–1000 copies/mL vs patients with viremia levels >1000 copies/mL were evaluated by χ2 test for trend. P < .05 was considered signiﬁcant.
Table 2. HIV-1 Genotyping Resistance Success Rate According
to Different Viremia Levels
Viremia Ranges,
Copies/mL
Overall
No. (%
Success)
Subtype
B, No.
(% Success)
Non-B,
No. (%
Success)
P
Valuea
Overall 12 828 (96.4) 10 212 (97.1) 2533 (96.1) .683
50–200 769 (67.2) 583 (72.9) 139 (66.2) .115
201–500 489 (88.1) 369 (90.0) 113 (86.7) .330
501–1000 444 (93.2) 329 (94.5) 112 (92.0) .328
1001–10 000 2435 (97.3) 1967 (98.0) 456 (96.9) .153
10 001–100 000 4845 (99.2) 3969 (99.3) 867 (99.2) .812
>100 000 3846 (99.5) 2995 (99.6) 846 (99.2) .159
Abbreviation: HIV-1, human immunodeficiency virus type 1.
The success of the genotypic resistance test in plasma samples from HIV-
1–infected patients was evaluated on the overall population with viremia
>50 copies/mL (N = 12 828) and according to subtype (B vs non-B), by
stratifying for viremia ranges. The rate of genotyping success in patients with
viremia <50 copies/mL was 17.5%.
a Potential differences in the rate of genotypic success in B and non-B subtypes
were evaluated by χ2 test (corrected for the population size, as appropriate) or
Fisher exact test, as appropriate. P < .05 was considered statistically
significant.
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The overall prevalence of samples with at least 1 PRM was
74% (Table 3). PI resistance in patients treated with PI/r was
in general less frequent than NRTI or NNRTI resistance
(40.5%, vs 66% and 77.7%; P < .001; Table 3).
If we consider PI resistance only in patients for whom a ﬁrst-
line regimen containing a PI/r was unsuccessful, the rate of re-
sistance dropped dramatically to 3.7%. By contrast, PI resistance
in patients treated with unboosted PIs was more similar to that
of those treated with an NRTI/NNRTI (61.7%) and remained
high also among patients tested at ﬁrst-line failure (46.6%).
The prevalence of resistance varied signiﬁcantly by viremia
strata (P < .001), and was characterized by a bell-shaped curve
in which the highest prevalence was in the 1001–10 000 cop-
ies/mL stratum, with lower prevalence values at lower and high-
er viremia strata. Detection of resistance was consistent also at
LLV. In particular, for viremia levels of 50–200 copies/mL,
NRTI resistance was 41.3%, NNRTI resistance was 40.2%, un-
boosted PI resistance was 51.6%, and PI/r resistance was 20.8%.
For viremia 201–500 copies/mL, rates of resistance were 62.3%,
69.3%, 30.8%, and 28.0% respectively, which increased, for vire-
mia 501–1000 copies/mL, to 67.1%, 79.5%, 79.2%, and 39.0%
for each respective drug class (Table 3). Therefore, substantial
levels of resistance can be detected also at LLV for all drug clas-
ses, with higher rates for NRTI and NNRTIs.
The distribution of drug resistance stratiﬁed for viremia was
similar also considering samples only from patients failing their
ﬁrst-line regimen. In particular, a consistent proportion of
NRTI and NNRTI resistance was found also at viremia levels
50–1000 copies/mL, whereas PI resistance was very low in sam-
ples from patients for whom a ﬁrst-line PI/r–containing regi-
men was unsuccessful (for viremia 50–200 copies/mL: NRTI
resistance, 19.2%; NNRTI resistance, 13.6%; PI/r resistance,
4.9%; for viremia 201–500 copies/mL: NRTI resistance, 38.3%;
NNRTI resistance, 54.5%; PI/r resistance, 0%; for viremia 501–
1000 copies/mL: NRTI resistance, 59.5%; NNRTI resistance,
73.3%; PI/r resistance, 7.1%).
The resistance to NRTI and NNRTI varied according to vire-
mia strata also by restricting the analysis during 2008–2012, with a
still-considerable prevalence of resistance in samples with viremia
levels ≤1000 copies/mL (Figure 2). By contrast, the prevalence of
PI resistance was not inﬂuenced by viremia strata because it was
very limited among all failures and was almost zero in patients
failing their ﬁrst-line PI/r–containing regimen.
Finally, by characterizing the prevalence of each single PRM
in samples genotyped during the years 2008–2012, no major
differences were found by analyzing samples with viremia
≤1000 vs >1000 copies/mL (Supplementary Table 2). In partic-
ular, only the NNRTI PRM K103N was found with a signiﬁ-
cantly higher prevalence in patients who failed treatment with
viremia >1000 copies/mL (43.3%) vs ≤1000 copies/mL (20.2%)
(P < .001, after multiple comparison correction).
Virologic Outcome
By Kaplan-Meier analysis, we found that the probability of
reaching viremia >1000 copies/mL after LLV was signiﬁcantly
higher in patients with resistance than in those without resis-
tance, as follows: at 24 weeks, 49.7% vs 4.2%; at 48 weeks,
58.1% vs 8.7%; at 72 weeks, 72.1% vs 15.2% (P < .001; data
not shown).
DISCUSSION
This study aimed at evaluating the reliability and usefulness of
GRT in HIV-1–infected patients with detectable LLV, in a large
data set of samples tested in 2 clinical centers in Italy. Our re-
sults showed that the genotyping success rate was 96% for the
overall population. In particular, this success rate was very high
also for viremia >200 copies/mL (about 88%), reaching about
93% at 501–1000 copies/mL and >97% above 1000 copies/mL.
Reasonable results in terms of success rate were obtained also
for samples with viremia between 50 and 200 copies/mL. The
ability to easily detect samples with LLV is mainly due to the
improvement of the ampliﬁcation step performed in our labo-
ratories. The success of sequencing was very similar between B
and non-B strains, thus suggesting that the subtype diversity
does not represent a limit. Our ﬁndings are in agreement with
those recently obtained in other studies, showing a high success
of ampliﬁcation and sequencing also at LLV [16, 19, 21, 26]. Our
results with LLV may not reﬂect the true population, but rather
reﬂect founder effects, especially when nested ampliﬁcation is
needed. Nevertheless, phylogenetic analysis conﬁrmed the reli-
ability and reproducibility in our laboratories of genotypic tests
at different viremia levels. Indeed, by evaluating 1613 pol se-
quences obtained from 470 patients with at least 2 GRTs per-
formed at different times and with different viremia levels
(ranging from <50 to >100 000 copies/mL), very high similarity
among sequences from the same patient was observed.
It should be emphasized that the additional step of the nested
PCR does not affect the total cost of genotyping test, because the
reagents used (Supplementary Methods) are inexpensive. In-
deed, by adding the nested PCR step, the total amount of
HIV-1 genotyping costs is increased only by about €10–€15
per sample performed. Therefore, we can conclude that the
use of GRT for treatment optimization in HIV-1–infected pa-
tients with treatment failure at LLV is in any case cost effective.
The clinical relevance of our ﬁndings is related to the fact that
in the last few years there has been an increased demand for
GRTs for drug-experienced patients failing with LLV (mainly
≤500 copies/mL, as shown in our analysis; Figure 1), explained
by a greater tendency to closely monitor patients in terms of re-
sponse to treatment and drug resistance. In our data set the pro-
portion of requests from patients failing therapy with LLV has
been about 30% since 2009.
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Table 3. Drug Resistance Stratiﬁed by Plasma Viremia Ranges
Viremia Range,
Copies/mL
All Samples Samples From Patients Taking NRTIs Samples From Patients Taking NNRTIs
Samples From Patients Taking
Ritonavir-Boosted PIs
Samples From Patients Taking
Ritonavir-Unboosted PIs
Resistance to Any Class NRTI Resistance NNRTI Resistance PI Resistance PI Resistance
No. %
P
Valuea
PRMs,
No.
P
Valueb No. %
P
Valuea
PRMs,
No.
P
Valueb No. %
P
Valuea
PRMs.
No.
P
Valueb No. %
P
Valuea
PRMs,
No.
P
Valueb No. %
P
Valuea
PRMs,
No.
P
Valueb
Overall ranges 3895 74.0 3 (0–7) 3761 66.0 1 (0–4) 1150 77.7 2 (1–2) 1977 40.5 0 (0–3) 632 61.7 1 (0–2)
50–200 396 52.8 <.001 1 (0–3) <.001 385 41.3 <.001 0 (0–1) <.001 82 40.2 <.001 0 (0–1) <.001 255 20.8 .842 0 (0–0) <.001 31 51.6 .672 1 (0–2) <.001
201–500 287 70.0 2 (0–4) 273 62.3 1 (0–3) 75 69.3 1 (0–2) 168 28.0 0 (0–1) 26 30.8 0 (0–1)
501–1000 242 74.0 3 (0–6) 228 67.1 1 (0–4) 78 79.5 1 (1–2) 123 39.0 0 (0–2) 24 79.2 1 (1–2)
1001–10 000 1102 86.1 4 (2–7) 1064 79.9 2 (1–4) 370 90.0 2 (1–3) 450 46.9 0 (0–3) 201 72.6 2 (0–3)
10 001–100 000 1212 76.7 4 (1–8) 1179 69.4 2 (0–4) 375 81.1 2 (1–2) 593 49.4 0 (0–4) 242 60.7 1 (0–2)
>100 000 656 63.0 2 (0–8) 632 52.8 1 (0–4) 170 64.7 1 (0–2) 388 38.4 0 (0–3) 108 50.0 0 (0–2)
The percentage of drug resistance and the median (IQR) number of PRMs were evaluated according to viremia ranges in 3895 patients with known therapeutic history and with at least 1 genotypic resistance test at
failure. Genotypic resistance tests were performed between May 1999 and December 2012; median year (IQR) of genotyping was 2006 (2003–2009).
Resistance to an antiretroviral drug class was defined by the presence of at least 1 PRM included in the mutation list paneled by the International AIDS Society in 2013 [34], considering the NRTIs, NNRTIs, and PIs. In
particular, we have defined (i) the resistance to any drug class in the overall samples analyzed; (ii) the resistance to NRTIs among samples from patients who received regimens that contained NRTIs; (iii) the resistance to
NNRTIs among samples from patients who received regimens that contained NNRTIs; (iv) the resistance to PIs among samples from patients who received regimens that contained ritonavir-boosted PIs; and (v) the
resistance to PIs among samples from patients who received regimens that contained ritonavir-unboosted PIs.
In all the analyses performed, P < .05 was considered statistically significant.
Abbreviations: %, proportion of samples with at least 1 PRM according to drug class; IQR , interquartile range; NNRTI, nonnucleos(t)ide reverse transcriptase inhibitor; NRTI, nucleos(t)ide reverse transcriptase inhibitor;
PI, protease inhibitor; PRM, primary resistance mutation.
a Potential differences in the percentage of resistance among the different viremia ranges were evaluated by the χ2 test for trend.
b Potential differences in the number of PRMs among the different viremia ranges were evaluated by the Kruskal-Wallis test.
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Moreover, our results corroborate the already discussed re-
cruitment about drug resistance presence also at viremia levels
≤1000 copies/mL [26, 35–37], underlining the importance of
GRTs also at LLV for the optimization of therapy in patients
under virologic failure. In this regard, it should be emphasized
that the optimization of the sequencing protocol in the last
years has led to a higher accuracy in detecting the PRMs for
each viremia level. In our study, a considerable prevalence of re-
sistance was found also at LLV among the samples analyzed
from patients for whom therapy was unsuccessful. This ﬁnding
proves that the detection of drug resistance is not a rare event in
these low viremia ranges.
A decline in the prevalence of PRMs was observed also at the
very high viremia strata among drug-experienced individuals.
This decline is likely to reﬂect suboptimal medication adher-
ence, with lower drug resistance selection [35].
A considerable prevalence of resistance to NRTIs and
NNRTIs at LLV was found also when the analysis was restricted
to 1317 samples from patients failing therapy in the last few
years. This prevalence can be due to the large usage of low-
genetic-barrier drugs such as lamivudine/emtricitabine or
efavirenz/nevirapine. By the evaluation of the effect of LLV re-
sistance on subsequent virologic outcome, we found that the
probability of reaching viremia >1000 copies/mL by 72 weeks
after LLV was signiﬁcantly higher in patients with resistance
than in those without resistance. This strongly suggests that
the early detection of resistance (when viremia is still <1000
copies/mL) may prevent the evolution toward (i) a virologic
failure with higher viremia and (ii) the accumulation of addi-
tional mutations, thus affecting the choice of future therapeutic
regimens. A potential limitation of this analysis could be it that
was performed only on a very small data set of patients. In line
with our data, a recent study, performed in a larger cohort of
patients, conﬁrmed that LLV resistance is predictive of subse-
quent virologic failure [37]. Taken together, these results rein-
force the concept that GRT may be useful in the management of
failure even at LLV.
Data presented in our study, in agreement with previous arti-
cles [35, 36] and with data recently presented [26, 37, 38], suggest
that newer guidelines may reconsider the importance of GRT in
clinical practice even at LLV. Indeed, despite the technical im-
provements achieved in the last few years, treatment guidelines
still do not usually recommend GRT in patients with a plasma
viral load ranging between 50 and 1000 copies/mL [2, 4].
In conclusion, our study, carried out in standard clinical prac-
tice, conﬁrms that drug resistance mutations can be detected even
at low viral load, regardless of the antiretroviral target genes, and
can remarkably reduce the current therapeutic options for further
regimens. Our ﬁndings emphasize the importance of using the
genotypic test at the ﬁrst treatment failures even at low viremia,
to guide the choice of an effective alternative regimen.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online
(http://cid.oxfordjournals.org/). Supplementary materials consist of data
provided by the author that are published to beneﬁt the reader. The posted
materials are not copyedited. The contents of all supplementary data are the
sole responsibility of the authors. Questions or messages regarding errors
should be addressed to the author.
Notes
Acknowledgments. We gratefully thank Andrea Biddittu, Massimiliano
Bruni, Luca Carioti, Fabio Continenza, Alberto Giannetti, Massimo Giulia-
ni, Anna Paciﬁci, Daniele Pizzi, andMarzia Romani for sequencing and data
management, together with all the members of the Resistance Group of the
National Institute for Infectious Diseases “Lazzaro Spallanzani”:
R. Acinapura, A. Ammassari, A. Antinori (Co-Chair), G. Anzidei,
F. Baldini, R. Bellagamba, E. Boumis, F. Ceccherini-Silberstein, S. Cerilli,
R. D’Arrigo, P. De Longis, G. D’Ofﬁzi, F. Forbici, L. Fabeni, S. Galati,
M. L. Giancola, E. Girardi, C. Gori, R. Libertone, G. Liuzzi, P. Lorenzini,
P. Marconi, S. Mosti, P. Narciso, V. Neri, E. Nicastri, C. F. Perno (Co-
Chair), C. Pinnetti, M. M. Santoro, P. Sette, V. Svicher, C. Tommasi,
V. Tozzi, U. Visco-Comandini, and M. Zaccarelli, and the Resistance
Group of University Hospital Tor Vergata: C. Alteri, M. Andreoni (Co-
Chair), D. Armenia, A. Bertoli, A. R. Buonomini, F. Ceccherini-Silberstein,
L. Dori, S. Giannella, T. Guenci, G Maffongelli, C. F. Perno (Co-Chair),
M. Pollicita, R. Salpini, M. M. Santoro, L. Sarmati, V. Svicher.
Financial support. This work was supported by the European Commis-
sion Framework 7 Programme (CHAIN, the Collaborative HIV and Anti-
HIV Drug Resistance Network, Integrated Project number 223131); the
European AIDS Treatment Network (NEAT, contract number LSHT/CT/
Figure 2. Resistance to nucleos(t)ide reverse transcriptase inhibitor
(NRTI), nonnucleos(t)ide reverse transcriptase inhibitor (NNRTI), or ritona-
vir-boosted protease inhibitor (PI/r) classes in samples collected from Jan-
uary 2008 to December 2012 stratiﬁed for plasma viremia ranges. Analysis
was performed on 1317 samples from patients for whom NRTI, NNRTI, or
ritonavir-boosted PI treatment failed. Resistance was deﬁned as the pres-
ence of at least 1 primary NRTI, NNRTI, or PI resistance mutation among
those paneled by the International AIDS Society–USA [34]. Potential dif-
ferences in the percentage of resistance among the different viremia rang-
es were evaluated by χ2 test for trend. P < .05 was considered signiﬁcant.
1162 • CID 2014:58 (15 April) • HIV/AIDS
 by guest on Septem
ber 2, 2015
http://cid.oxfordjournals.org/
D
ow
nloaded from
 
2006/037570); the Italian Ministry of Health (CUP: E81J10000000001, Ri-
cerca Corrente and Progetto AIDS, grant number 40H78); and the AVIRA-
LIA Foundation (unrestricted grant).
Potential conﬂicts of interest. M. M. S. has received funds for attending
symposia, speaking, and organizing educational activities from Abbott, Bris-
tol-Myers Squibb (BMS), Merck Sharp & Dohme (MSD), and
Janssen. A. Am. has received funds for advisory board membership from
MSD. E. N. has received funds for attending lectures (including services
on speakers’ bureaus) and grant research support from Janssen, Pﬁzer,
MSD, and ViiV Healthcare. N. P. has received funds for attending lectures
from Pﬁzer, Novartis, MSD, Astellas, Carefusion, and Johnson &
Johnson. M. A. has received funds for attending symposia, speaking, and
organizing educational activities as well as grant research support from Abb-
vie, BMS, Gilead Sciences, and ViiV Healthcare. F. C.-S. has received funds
for attending symposia, speaking, and organizing educational activities from
Abbott, MSD, Gilead, Janssen, ViiV Healthcare, Roche, and Virco. A. An.
has received funds for attending symposia, speaking, grant research support,
and consultancy from Abbvie, BMS, Gilead Sciences, MSD, Janssen, and
ViiV Healthcare. C. F. P. has received funds for attending symposia, speak-
ing, organizing educational activities, grant research support, consultancy,
and advisory board membership from Abbott, BMS, Gilead, MSD, Janssen,
Pﬁzer, Roche, and ViiV Healthcare. All other authors report no potential
conﬂicts.
All authors have submitted the ICMJE Form for Disclosure of Potential
Conﬂicts of Interest. Conﬂicts that the editors consider relevant to the con-
tent of the manuscript have been disclosed.
References
1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and
mortality among patients with advanced human immunodeﬁciency
virus infection. HIV Outpatient Study Investigators. N Engl J Med
1998; 338:853–60.
2. European AIDS Clinical Society Guidelines (EACS). Guidelines for the
clinical management and treatment of HIV infected adults in Europe.
Version 7.0, October 2013. Available at: http://www.eacsociety.org/
Portals/0/Guidelines_Online_131014.pdf. Accessed 22 July 2013.
3. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of
adult HIV infection: 2012 recommendations of the International Anti-
viral Society–USA panel. JAMA 2012; 308:387–402.
4. Guidelines for the use of antiretroviral agents in HIV-1-infected adults
and adolescents. February 2013. Available at: http://www.aidsinfo.nih.
gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 22 July 2013.
5. Lederman MM, Valdez H. Immune restoration with antiretroviral ther-
apies: implications for clinical management. JAMA 2000; 284:223–8.
6. Gutierrez F, Padilla S, Masiá M, et al. Clinical outcome of HIV-infected
patients with sustained virologic response to antiretroviral therapy:
long-term follow-up of a multicenter cohort. PLoS One 2006; 1:e89.
7. Moore RD, Keruly JC, Bartlett JG. Improvement in the health of HIV-
infected persons in care: reducing disparities. Clin Infect Dis 2012;
55:1242–51.
8. Geretti AM, Harrison L, Green H, et al. Effect of HIV-1 subtype on vi-
rologic and immunologic response to starting highly active antiretrovi-
ral therapy. Clin Infect Dis 2009; 48:1296–305.
9. Cozzi-Lepri A, Mussini C, Bonora S, et al. The chance of suppressing
viral load ≤80 copies/ml according to initial viral load and type of reg-
imen started: an observational study. In: 13th European AIDS Confer-
ence/European AIDS Clinical Society Guidelines (EACS). Belgrade,
Serbia, 12–15 October 2011. Abstract PE7.7/3.
10. Santoro MM, Armenia D, Alteri C, et al. Impact of pre-therapy viral
load on virological response to modern ﬁrst-line HAART. Antiv Ther
2013. doi:10.3851/IMP2531.
11. Gunthard HF, Wong JK, Ignacio CC, et al. Human immunodeﬁciency
virus replication and genotypic resistance in blood and lymph nodes
after a year of potent antiretroviral therapy. J Virol 1998; 72:2422–8.
12. Parkin NT, Deeks SG, Wrin MT, et al. Loss of antiretroviral drug sus-
ceptibility at low viral load during early virological failure in treatment-
experienced patients. AIDS 2000; 14:2877–87.
13. Aleman S, Soderbarg K, Visco-Comandini U, Sitbon G, Sonnerborg A.
Drug resistance at low viraemia in HIV-1–infected patients with antire-
troviral combination therapy. AIDS 2002; 16:1039–44.
14. Delaugerre C, Gallien S, Flandre P, et al. Impact of low-level-viremia on
HIV-1 drug-resistance evolution among antiretroviral treated-patients.
PLoS One 2012; 7:e36673. doi:10.1371/journal.pone.0036673.
15. Vandamme AM, Camacho RJ, Ceccherini-Silberstein F, et al. European
HIV Drug Resistance Guidelines Panel. European recommendations for
the clinical use of HIV drug resistance testing: 2011 update. AIDS Rev
2011; 13:77–108.
16. Mackie N, Dustan S, McClure MO, et al. Detection of HIV-1 antiretro-
viral resistance from patients with persistently low but detectable virae-
mia. J Virol Methods 2004; 119:73–81.
17. Nettles RE, Kieffer TL, Simmons RP, et al. Genotypic resistance in HIV-
1-infected patients with persistently detectable low-level viremia while
receiving highly active antiretroviral therapy. Clin Infect Dis 2004;
39:1030–7.
18. Gale HB, Kan VL, Shinol RC. Performance of the TruGene human im-
munodeﬁciency virus type 1 genotyping kit and OpenGene DNA se-
quencing system on clinical samples diluted to approximately 100
copies per milliliter. Clin Vaccine Immunol 2006; 13:235–8.
19. Waters L, Mandalia S, Asboe D. Successful use of genotypic resistance
testing in HIV-1-infected individuals with detectable viraemia between
50 and 1000 copies/mL. AIDS 2006; 20:778–9.
20. Mitsuya Y, Winters MA, Fessel WJ, et al. HIV-1 drug resistance geno-
type results in patients with plasma samples with HIV-1 RNA levels less
than 75 copies/mL. J Acquir Immune Deﬁc Syndr 2006; 43:56–9.
21. Cane PA, Kaye S, Smit E, et al. Genotypic antiretroviral drug resistance
at low viral loads in the UK. HIV Med 2008; 9:673–6.
22. Yang Z, Morrison R, Oates C, et al. HIV-1 genotypic resistance testing
on low viral load specimens using the Abbott ViroSeq HIV-1 genotyp-
ing system. Lab Med 2008; 39:671–3.
23. Pattery T, De Wolf H, Verlinden Y, et al. Efﬁciency of HIV-1 PR-RT
genotyping on clinical isolates with viral load less than 1000 copies/
mL: a 12 year analysis. In: 8th European HIV Drug Resistance Work-
shop, Sorrento, Italy, 2010. Poster 1.
24. Milia MG, Allice T, Gregori G, et al. Magnetic-silica based nucleic acid
extraction for human immunodeﬁciency virus type-1 drug-resistance
testing in low viremic patients. J Clin Virol 2010; 47:8–12.
25. Stelzl E, Troppan KT, Winkler M, et al. Optimized protocol for detec-
tion of HIV-1 drug mutations in patients with low viral load. J Virol
Methods 2010; 168:152–4.
26. Gonzalez-Serna A, Min JE, Woods C, Li J, Harrigan PR, Swenson LC.
Low level HIV viremia and drug resistance testing. In: 20th Program
and abstracts of the 20th Conference on Retroviruses and Opportunistic
Infections, Atlanta, 2013. Poster 601.
27. Ruelle J, Jnaoui K, Lefèvre I, et al. Comparative evaluation of the VER-
SANT HIV-1 RNA 1.0 kinetic PCR molecular system (kPCR) for the
quantiﬁcation of HIV-1 plasma viral load. J Clin Virol 2009;
44:297–301.
28. Paba P, Fabeni L, Ciccozzi M, et al. Performance evaluation of the
COBAS/TaqMan HIV-1 v2.0 in HIV-1 positive patients with low
viral load: a comparative study. J Virol Methods 2011; 173:399–402.
29. Sire JM, Vray M, Merzouk M, et al. Comparative RNA quantiﬁcation of
HIV-1 group M and non-M with the Roche Cobas AmpliPrep/Cobas
TaqManHIV-1 v2.0 and Abbott Real-Time HIV-1 PCR assays. J Acquir
Immune Deﬁc Syndr 2011; 56:239–43.
30. Ceccherini-Silberstein F, Gago F, Santoro M, et al. High sequence con-
servation of human immunodeﬁciency virus type 1 reverse transcriptase
under drug pressure despite the continuous appearance of mutations.
J Virol 2005; 79:10718–29.
31. Mukaide M, Sugiura W, Matuda M, et al. Evaluation of ViroSeq-HIV
version 2 for HIV drug resistance. Jpn J Infect Dis 2000; 53:203–5.
HIV/AIDS • CID 2014:58 (15 April) • 1163
 by guest on Septem
ber 2, 2015
http://cid.oxfordjournals.org/
D
ow
nloaded from
 
32. Cunningham S, Ank B, Lewis D, et al. Performance of the Applied Bio-
systems ViroSeq human immunodeﬁciency virus type 1 (HIV-1) geno-
typing system for sequence-based analysis of HIV-1 in pediatric plasma
samples. J Clin Microbiol 2001; 39:1254–7.
33. Kimura M. A simple method for estimating evolutionary rate of base
substitutions through comparative studies of nucleotide sequences.
J Mol Evol 1980; 16:111–20.
34. Johnson VA, Calvez V, Gunthard HF, et al. Update of the drug resistance
mutations in HIV-1: March 2013. Top Antivir Med 2013; 21:6–14.
35. Mackie NE, Phillips AN, Kaye S, et al. Antiretroviral drug resistance in
HIV-1-infected patients with low-level viremia. J Infect Dis 2010;
201:1303–7.
36. Prosperi MC, Mackie N, Di Giambenedetto S, et al. Detection of
drug resistance mutations at low plasma HIV-1 RNA load in a
European multicentre cohort study. J Antimicrob Chemother 2011;
66: 1886–96.
37. Swenson LC, Gonzalez-Serna A, Min J, Woods CK, Li JZ, Harrigan PR.
HIV drug resistance occurring during low-level viraemia is associated
with subsequent virological failure. Abstract 32. Program and abstracts
of the International Workshop on HIV & Hepatitis Virus Drug Resis-
tance and Curative Strategies (Toronto, Canada). Antiviral Ther 2013;
18(suppl 1):A40.
38. Assoumou L, Descamps D, Yerly S, et al. Prevalence of HIV-1 drug
resistance in treated patients with viral load >50 copies/mL in
2009: a French nationwide study. J Antimicrob Chemother 2013; 68:
1400–05.
39. Hochberg Y, Benjamini Y. More powerful procedures for multiple sig-
niﬁcance testing. Stat Med 1990; 9:811–8.
1164 • CID 2014:58 (15 April) • HIV/AIDS
 by guest on Septem
ber 2, 2015
http://cid.oxfordjournals.org/
D
ow
nloaded from
 
